Needham analyst Michael Matson (NYSE:MATX) reiterated a Buy rating on Cantel Medical (NYSE:CMD) Corp on Monday, setting a price target of $84, which is approximately 12.81% above the present share price of $74.46.
Matson expects Cantel Medical Corp to post earnings per share (EPS) of $0.58 for the fourth quarter of 2020.
The current consensus among 4 TipRanks analysts is for a Strong Buy rating of shares in Cantel Medical, with an average price target of $84.67.
The analysts price targets range from a high of $100 to a low of $70.
In its latest earnings report, released on 10/31/2020, the company reported a quarterly revenue of $297.03 million and a net profit of $50.35 million. The company's market cap is $3.15 billion.
According to TipRanks.com, Needham analyst Michael Matson is currently ranked with 5 stars on a 0-5 stars ranking scale, with an average return of 11.1% and a 65.19% success rate.
Cantel Medical Corp. engages in the development and manufacture of infection prevention products and services in the healthcare market. It operates through the following business segments: Medical, Life Sciences, Dental and Dialysis. The Medical segment designs, develops, manufactures, sells and installs a comprehensive offering of products and services comprising a complete circle of infection prevention solutions. The Life Sciences segment designs, develops, manufactures, sells and installs water purification systems for medical, pharmaceutical and other bacteria controlled applications. The Dental segment designs, manufactures, sells, supplies and distributes a broad selection of infection prevention healthcare products, the majority of which are single-use products used by dental practitioners. The Dialysis segment designs, develops, manufactures, sells and services reprocessing systems and sterilants for dialyzers as well as dialysate concentrates and supplies utilized for renal dialysis. Cantel Medical was founded on August 16, 1963 and is headquartered in Little Falls, NJ.